Comparison · NCT00311402-sae
Aggrenox Capsule vs Acetylsalicylic Acid (ASA) 81 mg Tablet: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Aggrenox Capsule vs Acetylsalicylic Acid (ASA) 81 mg Tablet: serious adverse events. Trial comparisons, record NCT00311402-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00311402-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.272 | 0.239 | 0.307 | wilson | |
| Risk in group 2 | 0.261 | 0.229 | 0.297 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0104 | -0.0378 | 0.0585 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.04 | 0.868 | 1.25 | log | |
| Odds ratio, group 1 over group 2 | 1.05 | 0.824 | 1.35 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Aggrenox Capsule than on Acetylsalicylic Acid (ASA) 81 mg Tablet | 96.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Aggrenox Capsule | Aggrenox (extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule), 2 capsules twice daily | 178 | 655 | EG000 |
| Group 2 | Acetylsalicylic Acid (ASA) 81 mg Tablet | ASA 81 mg, 1 tablet once daily | 167 | 639 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From day of first drug dose until 6 days after last dose, up to 874 days
Source ClinicalTrials.gov
Trial
- Title
- JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme
- NCT number
- NCT00311402
- Phases
- PHASE3
- Conditions
- Cerebrovascular Accident
- Interventions
- Aggrenox capsule, Acetylsalicylic Acid (ASA)
- Lead sponsor
- Boehringer Ingelheim
- Results first posted
- 2010-03-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00311402?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00311402-sae